• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

AstraZeneca India’s Q1 net profit declines 45 per cent

expresspharmaAugust 11, 2021

Tag: AstraZeneca , revenue , Q1

AstraZeneca Pharma India 9th reported a 45.03 per cent decline in its net profit to Rs 10.24 crores for the June-ended quarter. The company had posted a net profit of Rs 18.63 crores for the corresponding period of the previous fiscal, AstraZeneca Pharma India said in a regulatory filing.

Revenue from operations stood at Rs 175.40 crores for the quarter under consideration. It was Rs 193.57 crores for the same period a year ago, it added.

The company’s board of directors has declared an interim dividend of Rs 2 per equity share for the financial year 2021-22, the filing said.

Previous:Lincoln Pharmaceuticals reports standalone net profit of Rs 17.38 crores in Q1FY22

Next:BioNTech says repeats of its COVID-19 vaccine better than devising new one, for now

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

AstraZeneca India’s Q1 net profit declines 45 per cent | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Coenzyme Q10

Coenzyme Q10
bulk price fat soluble ubiquinone coq10 powder 98% coenzyme Q10

bulk price fat soluble ubiquinone coq10 powder 98% coenzyme Q10
Coenzyme Q10

Coenzyme Q10
Coenzyme   Q10 Capsules

Coenzyme   Q10 Capsules
(E)-CHLORO-2-METHYL-1-PHENYLSULFONYL-2-BUTENE (INTERMEDIATES OF COENZYME Q10)

(E)-CHLORO-2-METHYL-1-PHENYLSULFONYL-2-BUTENE (INTERMEDIATES OF COENZYME Q10)
Coenzyme Q10

Coenzyme Q10
Coenzyme Q10 ; CoQ10

Coenzyme Q10 ; CoQ10
Coenzyme Q10 (Powder 10% Cws)

Coenzyme Q10 (Powder 10% Cws)
Coenzyme Q10 Water Soluble

Coenzyme Q10 Water Soluble
Coenzyme Q10

Coenzyme Q10

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service